Court’s Nod to Proceed Further with Drug Safety Trial

Proceedings brought by a breast cancer patient against a well known drug corporation will make a move ahead after the Supreme Court did not allow any intervention in the argument.

The justices without any statement on Monday turned away a plea from Wyeth Pharmaceuticals, manufacturer of drugs for hormone replacement therapy.

An Arkansas panel of adjudicators had honored $2.75 million in compensatory damages to Donna Scroggin, who asserted that she developed the cancer from drugs that were manufactured by Wyeth and Upjohn Corp., both Companies that are now possessed by Pfizer Inc.

The Little Rock dweller in argument said that the medicines Prempro and Premarin did not have sufficient safety warnings regarding the augmented risks for developing breast cancer.

Wyeth had requested the high court to sack that jury grant and to block a second trial that is to be restricted to deciding disciplinary damages.

A federal appeals court in St. Louis has passed orders that separate retrial would take place, amongst questions about the proof of an ex- Food and Drug Administration official who testified on Scroggin's behalf in the original trial.

Depending on the outcome of the punitive damages portion of the case, Pfizer could appeal again to the Supreme Court.

Chief Justice John Roberts backed out of consideration of the current appeal because he owns Pfizer stock.